Hyper Corporation Inc. (KOSDAQ:065650)

Market Cap	55.65B
Revenue (ttm)	62.84B
Net Income (ttm)	-70.68B
Shares Out	13.31M
EPS (ttm)	-5,769.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,956
Average Volume	154,533
Open	4,230.00
Previous Close	4,230.00
Day's Range	4,090.00 - 4,365.00
52-Week Range	1,424.00 - 11,592.00
Beta	1.77
RSI	50.07
Earnings Date	Aug 13, 2025

About Hyper Corporation

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and w...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 1997
• Employees: 46
• Stock Exchange: KOSDAQ
• Ticker Symbol: 065650

Financial Performance

In 2024, Hyper Corporation's revenue was 58.46 billion, an increase of 36.33% compared to the previous year's 42.88 billion. Losses were -80.36 billion, 3999.0% more than in 2023.